MétaCan
Menu
Back to cohort
Record W2985558334 · doi:10.6004/jnccn.2019.0039

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

2019· article· en· W2985558334 on OpenAlexaff
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath, Joyce F. Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac‐Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh

Bibliographic record

VenueJournal of the National Comprehensive Cancer Network · 2019
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsAstraZeneca (Canada)
FundersGenentechPuma BiotechnologyClovis OncologyEisaiNational Comprehensive Cancer NetworkGilead SciencesNovartis Pharmaceuticals CorporationBiogenCelgeneBristol-Myers SquibbAstraZenecaGenomic HealthAmgen
KeywordsMedicineBevacizumabOvarian cancerChemotherapyOncologyCytoreductive surgeryInternal medicineDiseaseCancerHyperthermic intraperitoneal chemotherapyIntensive care medicine

Abstract

fetched live from OpenAlex

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.036
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.047
Threshold uncertainty score0.157

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.036
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0040.005
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0030.002
Research integrity0.0050.004
Insufficient payload (model declined to judge)0.0470.026

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.053
GPT teacher head0.349
Teacher spread0.296 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations332
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the National Comprehensive Cancer NetworkSame topicOvarian cancer diagnosis and treatmentFrench-language works237,207